Literature DB >> 16024913

HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney.

Ji-Young Lee1, Jenelle M Timmins, Anny Mulya, Thomas L Smith, Yiwen Zhu, Edward M Rubin, Jeffrey W Chisholm, Perry L Colvin, John S Parks.   

Abstract

Patients homozygous for Tangier disease have a near absence of plasma HDL as a result of mutations in ABCA1 and hypercatabolize normal HDL particles. To determine the relationship between ABCA1 expression and HDL catabolism, we investigated intravascular remodeling, plasma clearance, and organ-specific uptake of HDL in mice expressing the human apolipoprotein A-I (apoA-I) transgene in the Abca1 knockout background. Small HDL particles (7.5 nm), radiolabeled with (125)I-tyramine cellobiose, were injected into recipient mice to quantify plasma turnover and the organ uptake of tracer. Small HDL tracer was remodeled to 8.2 nm diameter particles within 5 min in human apolipoprotein A-I transgenic (hA-I(Tg)) mice (control) and knockout mice. Decay of tracer from plasma was 1.6-fold more rapid in knockout mice (P < 0.05) and kidney uptake was twice that of controls, with no difference in liver uptake. We also observed 2-fold greater hepatic expression of ABCA1 protein in hA-I(Tg) mice compared with nontransgenic mice, suggesting that overexpression of human apoA-I stabilized hepatic ABCA1 protein in vivo. We conclude that ABCA1 is not required for in vivo remodeling of small HDLs to larger HDL subfractions and that the hypercatabolism of normal HDL particles in knockout mice is attributable to a selective catabolism of HDL apoA-I by the kidney.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024913     DOI: 10.1194/jlr.M500179-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

1.  Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo.

Authors:  Soonkyu Chung; Janet K Sawyer; Abraham K Gebre; Nobuyo Maeda; John S Parks
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

Review 2.  Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Authors:  Valentina Kon; Haichun Yang; Sergio Fazio
Journal:  Arch Med Res       Date:  2015-05-23       Impact factor: 2.235

3.  Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Richard J Charnigo; Ailing Ji; Nancy R Webb; Frederick C de Beer; Deneys R van der Westhuyzen
Journal:  J Lipid Res       Date:  2016-03-27       Impact factor: 5.922

4.  Targeted Deletion of Hepatocyte Abca1 Increases Plasma HDL (High-Density Lipoprotein) Reverse Cholesterol Transport via the LDL (Low-Density Lipoprotein) Receptor.

Authors:  Alexander C Bashore; Mingxia Liu; Chia-Chi C Key; Elena Boudyguina; Xianfeng Wang; Caitlin M Carroll; Janet K Sawyer; Adam E Mullick; Richard G Lee; Shannon L Macauley; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-06-06       Impact factor: 8.311

5.  A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II.

Authors:  Jonas Heilskov Graversen; Graciela Castro; Abdelmejid Kandoussi; Henning Nielsen; Erik Ilsø Christensen; Anthony Norden; Søren Kragh Moestrup
Journal:  Lipids       Date:  2008-03-19       Impact factor: 1.880

6.  Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL.

Authors:  Anny Mulya; Ji-Young Lee; Abraham K Gebre; Elena Y Boudyguina; Soon-Kyu Chung; Thomas L Smith; Perry L Colvin; Xian-Cheng Jiang; John S Parks
Journal:  J Lipid Res       Date:  2008-06-25       Impact factor: 5.922

7.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

Review 8.  HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications.

Authors:  Alan T Remaley; Marcelo Amar; Dmitri Sviridov
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

Review 9.  Kidneys: key modulators of high-density lipoprotein levels and function.

Authors:  Haichun Yang; Agnes B Fogo; Valentina Kon
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

10.  Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupting glucose-derived cholesterol synthesis in liver as revealed by the [U-C(6)]-d-glucose tracer in mice.

Authors:  Richard D Beger; Deborah K Hansen; Laura K Schnackenberg; Brandie M Cross; Javad J Fatollahi; F Tracy Lagunero; Zoltan Sarnyai; Laszlo G Boros
Journal:  Metabolomics       Date:  2009-03-31       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.